Longevity Pipeline
BioAge Labs
Apelin/APJ agonism; NLRP3 · Obesity (muscle preservation), inflammaging
Phase 2GLP-1 & the Incretin Boom
Mechanism
Apelin/APJ agonism; NLRP3
Intervention class
Small molecule
Indication
Obesity (muscle preservation), inflammaging
Stage
Phase 2
Evidence
human
Funding
NASDAQ: BIOA · IPO'24
Backers
Public (ex-a16z, Andreessen)
Overview
Discovery from human aging cohorts (the 'BioAge' data engine). Lead azelaprag aimed at preserving muscle during GLP-1 weight loss — a sharp commercial wedge that rides the obesity wave while being rooted in aging biology.
Technology
BioAge Labs works in GLP-1 & the Incretin Boom — The gut hormone that reset obesity — and is now eyeing aging itself.
Read the GLP-1 & the Incretin Boom brief →Related companies
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.